A Combinatorial Code for CPEB-Mediated c-myc Repression

Cells. 2023 Oct 6;12(19):2410. doi: 10.3390/cells12192410.

Abstract

During early embryonic development, the RNA-binding protein CPEB mediates cytoplasmic polyadenylation and translational activation through a combinatorial code defined by the cy-toplasmic polyadenylation element (CPE) present in maternal mRNAs. However, in non-neuronal somatic cells, CPEB accelerates deadenylation to repress translation of the target, including c-myc mRNA, through an ill-defined cis-regulatory mechanism. Using RNA mutagenesis and electrophoretic mobility shift assays, we demonstrated that a combination of tandemly arranged consensus (cCPE) and non-consensus (ncCPE) cytoplasmic polyadenylation elements (CPEs) constituted a combinatorial code for CPEB-mediated c-myc mRNA decay. CPEB binds to cCPEs with high affinity (Kd = ~250 nM), whereas it binds to ncCPEs with low affinity (Kd > ~900 nM). CPEB binding to a cCPE enhances CPEB binding to the proximal ncCPE. In contrast, while a cCPE did not activate mRNA degradation, an ncCPE was essential for the induction of degradation, and a combination of a cCPE and ncCPEs further promoted degradation. Based on these findings, we propose a model in which the high-affinity binding of CPEB to the cCPE accelerates the binding of the second CPEB to the ncCPEs, resulting in the recruitment of deadenylases, acceleration of deadenylation, and repression of c-myc mRNAs.

Keywords: CPEB; RNA-binding protein; mRNA deadenylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Oocytes* / metabolism
  • RNA / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA-Binding Proteins / metabolism
  • Transcription Factors / metabolism
  • mRNA Cleavage and Polyadenylation Factors* / metabolism

Substances

  • mRNA Cleavage and Polyadenylation Factors
  • RNA
  • RNA, Messenger
  • RNA-Binding Proteins
  • Transcription Factors

Grants and funding

This research was funded by the JSPS Grant-in-Aid for Scientific Research (B) (JP21H02406 to S.H.) and Early-Career Scientists (JP20K15719 and 22K06925 to K.O.) and the JSPS Grant-in-Aid for Scientific Research (C) (JP20K06925 to K.O.); Program on the Innovative Development and the Application of New Drugs for Hepatitis B from Japan Agency for Medical Research and Development, AMED (JP22fk0310515s0401 to S.H.); and the TAKEDA Science Foundation (JOSEI32912 to S.H.).